# The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

> **NCT06139419** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 114 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **RADIATION:** definitive radiotherapy
- **DRUG:** induction chemo-immunotherapy
- **DRUG:** concurrent chemotherapy
- **DRUG:** Immunotheapy consolidation
- **DRUG:** Thymosin Alpha1

## Key facts

- **NCT ID:** NCT06139419
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-25
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06139419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06139419, "The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06139419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*